
Congress trades
Sarepta Therapeutics, Inc. (SRPT)
NASDAQ · Healthcare · 17 congress trades · last filed 1 year ago
About Sarepta Therapeutics, Inc.
from the company's filings and listing, as of Oct 21, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Michael E. Severino
- Employees
- 835
- Listed since
- Jun 4, 1997
- Market value
- $2.0B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$1.30
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 4, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 5, 2026 | -$0.05 | $0.22 | $401.3M | $366.4M | EPS miss, GAAPRevenue beat |
| Q1 FY2026reported May 6, 2026 | $3.16 | $0.98 | $730.8M | $474.2M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 25, 2026 | -$3.58 | -$1.03 | $442.9M | $369.6M | EPS missRevenue beat |
| Q3 FY2025reported Nov 3, 2025 | -$1.80 | -$0.73 | $399.4M | $335.8M | EPS miss, GAAPRevenue beat |
| Q2 FY2025reported Aug 6, 2025 | $2.02 | $0.83 | $611.1M | $530.7M | EPS beatRevenue beat |
| Q1 FY2025reported May 6, 2025 | -$4.60 | -$0.87 | $744.9M | $687.5M | EPS miss, GAAPRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 24, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Douglas S. IngramChief Executive Officer | $1.2M | $6.0M | $669K | $7.8M |
| Louise Rodino-Klapac, Ph.D.President, Research and Development and Technical Operations | $753K | $2.6M | $1.1M | $4.5M |
| Ian M. EstepanPresident, Chief Operating Officer | $741K | $2.6M | $1.1M | $4.4M |
| Ryan H. WongExecutive Vice President, Chief Financial Officer | $480K | $2.2M | $553K | $3.2M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 2 executives who have since left the company are named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $341.3M | 18,994,958 | +28.7% | 18.02% |
| State Street Corp | $160.2M | 8,916,090 | +34.8% | 8.49% |
| Vanguard Portfolio Management LLC | $150.5M | 8,377,470 | +26.2% | 7.95% |
| Two Sigma Investments, LP | $82.6M | 4,598,735 | +0.1% | 4.36% |
| Vanguard Capital Management LLC | $82.5M | 4,591,755 | +0.3% | 4.36% |
| First Trust Advisors LP | $78.5M | 4,365,951 | +5.6% | 4.14% |
| AQR Capital Management LLCCliff Asness | $76.9M | 4,325,689 | -32.8% | 4.10% |
| Geode Capital Management, LLC | $49.8M | 2,771,758 | +39.4% | 2.63% |
| Erste Asset Management GmbH | $45.5M | 2,568,945 | -13.5% | 2.44% |
| Marshall Wace, LLP | $39.6M | 2,206,022 | +204.3% | 2.09% |
| Morgan Stanley | $39.6M | 2,202,641 | -15.2% | 2.09% |
| Aberdeen Group PLC | $39.4M | 2,194,948 | -5.3% | 2.08% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Congress trades in SRPT
17 disclosures of 17 on record · median 35d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | -67.5%After the saleS&P 500 +41.0% · -108.5 pts vs S&P 500 | Apr 14, 2025 | May 6, 2025 | 22d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -83.6%S&P 500 +69.2% · -152.8 pts vs S&P 500 | Jul 14, 2023 | Aug 21, 2023 | 38d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -86.3%After the saleS&P 500 +74.1% · -160.4 pts vs S&P 500 | Jun 13, 2023 | Jul 11, 2023 | 28d |
| Daniel S. Goldman | Stock | Sale | $15,001 - $50,000 | -87.4%After the saleS&P 500 +85.6% · -173.0 pts vs S&P 500 | Apr 10, 2023 | May 19, 2023 | 39d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -88.6%S&P 500 +87.9% · -176.6 pts vs S&P 500 | Mar 6, 2023 | Apr 20, 2023 | 45d |
| Daniel S. Goldman | Stock | Purchase | $15,001 - $50,000 | -88.6%S&P 500 +87.9% · -176.6 pts vs S&P 500 | Mar 6, 2023 | Apr 17, 2023 | 42d |
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | -85.8%After the saleS&P 500 +87.1% · -172.9 pts vs S&P 500 | Jan 31, 2023 | Feb 24, 2023 | 24d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -85.9%After the saleS&P 500 +117.1% · -203.0 pts vs S&P 500 | Nov 6, 2020 | Dec 9, 2020 | 33d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -87.2%S&P 500 +124.7% · -211.8 pts vs S&P 500 | Sep 14, 2020 | Oct 14, 2020 | 30d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | -88.9%After the saleS&P 500 +138.2% · -227.1 pts vs S&P 500 | Jun 10, 2020 | Jul 17, 2020 | 37d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -86.6%S&P 500 +139.7% · -226.3 pts vs S&P 500 | Dec 13, 2019 | Jan 6, 2020 | 24d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -78.7%S&P 500 +159.4% · -238.1 pts vs S&P 500 | Oct 10, 2019 | Nov 15, 2019 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -78.8%S&P 500 +156.7% · -235.5 pts vs S&P 500 | Oct 11, 2019 | Nov 15, 2019 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -85.7%S&P 500 +164.8% · -250.5 pts vs S&P 500 | Apr 9, 2019 | May 14, 2019 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -86.8%S&P 500 +172.9% · -259.7 pts vs S&P 500 | Mar 11, 2019 | Apr 16, 2019 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -87.3%S&P 500 +172.0% · -259.4 pts vs S&P 500 | Feb 26, 2019 | Mar 8, 2019 | 10d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -88.3%S&P 500 +172.2% · -260.5 pts vs S&P 500 | Feb 27, 2019 | Mar 8, 2019 | 9d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in SRPT, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded SRPT?
Gilbert Ray Cisneros, Jr., Josh Gottheimer and Daniel S. Goldman disclosed SRPT transactions in the filings shown here.
How quickly are SRPT trades disclosed?
Congressional disclosures took a median of 35 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.
